Integra LifeSciences (NASDAQ:IART) Lowered to Hold at StockNews.com

StockNews.com downgraded shares of Integra LifeSciences (NASDAQ:IART) from a buy rating to a hold rating in a research note published on Tuesday.

A number of other equities research analysts have also recently weighed in on the company. Truist Financial lowered their price target on Integra LifeSciences from $46.00 to $41.00 and set a hold rating on the stock in a report on Friday, March 1st. Citigroup upgraded Integra LifeSciences from a sell rating to a neutral rating and set a $38.00 price target on the stock in a report on Wednesday, April 3rd. Finally, JMP Securities lowered their price target on Integra LifeSciences from $55.00 to $49.00 and set a market outperform rating on the stock in a report on Thursday, February 29th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Integra LifeSciences currently has an average rating of Hold and a consensus target price of $44.89.

Integra LifeSciences Stock Performance

Shares of IART stock opened at $29.17 on Tuesday. The company has a market cap of $2.29 billion, a price-to-earnings ratio of 35.14, a price-to-earnings-growth ratio of 0.85 and a beta of 1.12. The stock has a 50 day simple moving average of $35.02 and a 200-day simple moving average of $38.71. Integra LifeSciences has a 12-month low of $27.18 and a 12-month high of $56.21. The company has a current ratio of 3.45, a quick ratio of 2.18 and a debt-to-equity ratio of 0.94.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.01). The business had revenue of $397.00 million for the quarter, compared to analysts’ expectations of $399.30 million. Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The business’s quarterly revenue was down .3% on a year-over-year basis. During the same period last year, the company posted $0.94 earnings per share. On average, equities analysts forecast that Integra LifeSciences will post 3.19 EPS for the current year.

Institutional Investors Weigh In On Integra LifeSciences

Several hedge funds have recently made changes to their positions in the business. Arizona State Retirement System boosted its holdings in shares of Integra LifeSciences by 1.3% during the third quarter. Arizona State Retirement System now owns 20,988 shares of the life sciences company’s stock worth $802,000 after purchasing an additional 279 shares during the last quarter. Cardinal Capital Management boosted its holdings in shares of Integra LifeSciences by 1.6% during the fourth quarter. Cardinal Capital Management now owns 22,101 shares of the life sciences company’s stock worth $962,000 after purchasing an additional 347 shares during the last quarter. Hexagon Capital Partners LLC boosted its holdings in shares of Integra LifeSciences by 123.3% during the fourth quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company’s stock worth $29,000 after purchasing an additional 370 shares during the last quarter. Inspire Investing LLC boosted its holdings in shares of Integra LifeSciences by 5.1% during the third quarter. Inspire Investing LLC now owns 8,004 shares of the life sciences company’s stock worth $306,000 after purchasing an additional 392 shares during the last quarter. Finally, State of Michigan Retirement System boosted its holdings in shares of Integra LifeSciences by 2.5% during the first quarter. State of Michigan Retirement System now owns 16,690 shares of the life sciences company’s stock worth $592,000 after purchasing an additional 400 shares during the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.